eligibility_summary
Adults 18–75, ECOG 0–1, colorectal cancer with metastatic/recurrent disease not surgically curable, RAS‑WT liver mets, treatment‑naive, ≥1 measurable lesion (RECIST 1.1), adequate organ/marrow function, contraception/negative pregnancy test. Exclude: pregnancy/lactation, drug allergy, GI bleed/obstruction risk, thromboembolism (except PICC), infection, uncontrolled HTN, brain mets, significant comorbidities, ≥Grade 2 irAEs/other toxicities, recent therapy/trial <4 wks, or per investigator.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II single-arm study in untreated RAS–wild-type colorectal cancer with liver metastases selected by ctDNA superselective negative genes. Interventions: cetuximab (EGFR-targeting IgG1 monoclonal antibody) plus chemotherapy. Regimen: XELOX induction (capecitabine, an oral prodrug of 5‑FU, oxaliplatin, a platinum DNA crosslinker), then biweekly FOLFOX (5‑FU, an antimetabolite that inhibits thymidylate synthase, leucovorin, a 5‑FU modulator that stabilizes the TS–5‑FU complex, oxaliplatin). Mechanisms/targets: Cetuximab blocks EGFR ligand binding and receptor activation, suppressing downstream MAPK/ERK and PI3K/AKT signaling in EGFR-expressing, RAS–WT tumor cells, and may trigger ADCC via Fc. 5‑FU/leucovorin target DNA synthesis (TS inhibition), and oxaliplatin induces cytotoxic DNA damage/crosslinks.